The Effect of Decreasing the Dosage of Cyclosporine A 0.05% on Dry Eye Disease After 1 Year of Twice-Daily Therapy

Abstract

For patients with dry eye that has been controlled with tCSA twice daily for at least 1 year, decreasing to tCSA once daily may still allow suppression of the dry eye disease.

Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease

“…A total of 3 additional studies used CsA 0.05%: 1 used a 0.05% CsA ophthalmic emulsion versus placebo comparing the result to a topical vitamin A treatment in 150 patients;16 1 evaluated CsA 0.05% ophthalmic emulsion twice a day versus once a day in 100 patients for 24 weeks;23 and 1 study evaluated CsA 0.05% in oil in 51 patients for 12 weeks 25…”

“…Among the RTCs on CsA 0.05%, eight studies used the commercially available CsA eyedrops Restasis 12 13 15–17 20 21 23…”

“…Specifically, the type I Schirmer test (without anaesthesia) was performed in eight trials 9 11 13 16 18 19 21 22. The type II Schirmer test (with anaesthesia) was used in seven trials 12 14 15 17 20 23 25. Two studies used Schirmer I and II tests 10 24.…”

Ophthalmic manifestation of leukemia

“…В тяжёлых случаях описано увеличение крат-ности его инстилляций [25]. Имеются данные о сокращении кратности инстилляций до 1 раза в сутки после стабилизации течения ССГ, однако у 14-20 % пациентов это вызывало ухудшение течения заболевания и требовало возврата к дву-кратному режиму инстилляций [105].…”

Evaluation of Corneal Morphologic and Functional Parameters After Use of Topical Cyclosporine-A 0.05% in Dry Eye

“…This results in a self-perpetuating cycle of chronic inflammation and continual decrease in tear production. [8][9][10] A cyclosporine 0.05% ophthalmic emulsion (Restasis; Allergan, Irvine, CA) was approved by the United States Food and Drug Administration for treatment of dry eye syndrome in 2003. Topical cyclosporine blocks T-cell activation and secondarily inhibits the inflammatory process.…”